The drug–drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4

References

• Abdel-Rahman O. (2013). Systemic therapy for hepatocellular carcinoma (HCC): from bench to bedside. J Egypt Natl Canc Inst 25:165–71
   PubMedGoogle Scholar
• Abdel-Rahman O. (2014). Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): from bench to bedside. Crit Rev Oncol Hematol 94:45–54
   PubMed Web of Science ®Google Scholar
• Abdulghani J, Allen JE, Dicker DT, et al. (2013). Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis. PLoS One 8:e75414
   PubMed Web of Science ®Google Scholar
• Aderhold C, Faber A, Grobschmidt GM, et al. (2013). Small molecule-based chemotherapeutic approach in p16-positive and negative HNSCC in vitro. Anticancer Res 33:5385–93
   PubMed Web of Science ®Google Scholar
• Agarwal S, Elmquist WF. (2012). Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance. Mol Pharm 9:678–84
   PubMed Web of Science ®Google Scholar
• Alsaied OA, Sangwan V, Banerjee S, et al. (2014). Sorafenib and triptolide as combination therapy for hepatocellular carcinoma. Surgery 156:270–9
   PubMed Web of Science ®Google Scholar
• Andriamanana I, Gana I, Duretz B, Hulin A. (2013). Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 926:83–91
   PubMed Web of Science ®Google Scholar
• Bayyoud T, Hofmann J, Spitzer M, et al. (2014). Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells. Curr Eye Res 39:149–54
   PubMed Web of Science ®Google Scholar
• Bazzola L, Foroni C, Andreis D, et al. (2015). Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. Br J Cancer 112:52–60
   PubMed Web of Science ®Google Scholar
• Bertino G, Di Carlo I, Ardiri A, et al. (2013). Systemic therapies in hepatocellular carcinoma: present and future. Future Oncol 9:1533–48
   PubMed Web of Science ®Google Scholar
• Bobin-Dubigeon C, Heurgue-Berlot A, Bouche O, et al. (2011). A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis. Ther Drug Monit 33:705–10
   PubMed Web of Science ®Google Scholar
• Cao H, Wang Y, He X, et al. (2015). Co-delivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma. Mol Pharm 12:922–31
   PubMed Web of Science ®Google Scholar
• Escudero-Ortiz V, Perez-Ruixo JJ, Valenzuela B. (2014). Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice. Ther Drug Monit 36:317–25
   PubMed Web of Science ®Google Scholar
• Fukudo M, Ito T, Mizuno T, et al. (2014). Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma. Clin Pharmacokinet 53:185–96
   PubMed Web of Science ®Google Scholar
• Gillani TB, Rawling T, Murray M. (2014). Cytochrome P450-mediated biotransformation of sorafenib and its N-oxide metabolite: implications for cell viability and human toxicity. Chem Res Toxicol [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Gotze L, Hegele A, Metzelder SK, et al. (2012). Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 413:143–9
   PubMed Web of Science ®Google Scholar
• Li L, Zhao M, Navid F, et al. (2010). Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 878:3033–8
   PubMed Web of Science ®Google Scholar
• Luethi D, Durmus S, Schinkel AH, et al. (2014). Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomed Chromatogr 28:1366–70
   PubMed Web of Science ®Google Scholar
• Manda VK, Avula B, Ali Z, et al. (2013). Characterization of in vitro ADME properties of diosgenin and dioscin from Dioscorea villosa. Planta Med 79:1421–8
   PubMed Web of Science ®Google Scholar
• Polasek TM, Elliot DJ, Lewis BC, Miners JO. (2004). Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996–1007
   PubMed Web of Science ®Google Scholar
• Qi XY, Liang SC, Ge GB, et al. (2013). Inhibitory effects of sanguinarine on human liver cytochrome P450 enzymes. Food Chem Toxicol 56:392–7
   PubMed Web of Science ®Google Scholar
• Shimada M, Okawa H, Maejima T, et al. (2014). A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients. Tohoku J Exp Med 233:103–12
   PubMed Web of Science ®Google Scholar
• Sparidans RW, Durmus S, Schinkel AH, et al. (2012). Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma. J Chromatogr B Analyt Technol Biomed Life Sci 889890:144–7
   Web of Science ®Google Scholar
• Tang SC, de Vries N, Sparidans RW, et al. (2013). Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib. J Pharmacol Exp Ther 346:486–94
   PubMed Web of Science ®Google Scholar
• Wang XQ, Fan JM, Liu YO, et al. (2011). Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat. Int J Pharm 419:339–46
   PubMed Web of Science ®Google Scholar
• Yeo KR, Yeo WW. (2001). Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 51:461–70
   PubMed Web of Science ®Google Scholar
• Zhang L, Hu P, Chen X, Bie P. (2014a). Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis. PLoS One 9:e100305
   PubMed Web of Science ®Google Scholar
• Zhang XJ, Zhang TY, Yu FF, et al. (2014b). Risk of treatment-related mortality with sorafenib in patients with cancer. Asian Pac J Cancer Prev 14:6681–6
   PubMed Web of Science ®Google Scholar
• Zhao M, Rudek MA, He P, et al. (2007). A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. J Chromatogr B Analyt Technol Biomed Life Sci 846:1–7
   PubMed Web of Science ®Google Scholar
• Zimmerman EI, Roberts JL, Li L, et al. (2012). Ontogeny and sorafenib metabolism. Clin Cancer Res 18:5788–95
   PubMed Web of Science ®Google Scholar